Innovations in Drug Delivery Part II, a free online event on July 15, will feature novel technologies and innovative solutions to current challenges.
Cryoport will provide cold chain logistics to TiGenix as it conducts phase Ib/IIa allogeneic adipose‐derived stem cells for the treatment of sepsis.
Swedish drugmaker Xbrane Biopharma says it is teaming with CR Pharma to bring its Lucentis (ranibizumab) biosimilar to China.
bluebird bio Inc has hired apceth Biopharma GmbH to make its candidate ALD cell therapy Lenti-D and its thalassemia treatment LentiGlobin for the European market.
TxCell is working on new ways of delivering its Crohn's disease therapy Ovasave that will replace the somewhat unusual method it is using in clinical trials.
Biosimilars will help sustain biopharma innovation but will not erode sales like generic drugs, J&J’s CEO Alex Gorsky told investors last week.
Transgene will close a biomanufacturing facility with the loss of 120 jobs to cut costs after Novartis pulled out of an immunotherapy collaboration last year.
Sartorius has expanded its biopharma services to include contract testing by buying CRO BioOutsource.
Ensuring drugs, APIs and excipients are safe will be a focus for the EMA, which says it will explore supplier inspection databases and using trade deals like TTIP to promote GMP standards globally.
Sanofi has partnered with Dutch biotechnology spin-out Lead Pharma to discover autoimmune drugs that target ROR gamma t hormone receptors.
Big biotech firms risk the empty pipeline pitfalls of old pharma if they protect their drugs from biosimilars rather than invest in innovation, ex-Teva CEO Jeremy Levin warns.
The EMA has defended its decision to redact three Humira clinical study reports, arguing that the information held back was ‘commercially confidential.’
President Obama in his State of the Union address has called for the power to personally make stronger trade agreements – bringing divisive EU deal TTIP closer to adoption and angering campaigners for drugs access.
MedImmune’s neurodegenerative disease partnership with the University of Cambridge is about working with “great scientists with great brains” according to a spokeswoman for parent company, AstraZeneca.
In direct opposition to a petition raised by GPhA (Generic Pharmaceutical Association) and Novartis, AbbVie, Genentech and Amgen are all looking for the US FDA to call for new non-proprietary names for biosimilars.
Big Pharma takeovers of small biopharmaceutical companies to refill pipelines increased the volume and value of dealmaking in Q4 according to a new report by PwC.
Biopharmas should stop green lighting safe, mediocre candidates and focus on developing drugs that are genuine scientific breakthroughs to control spiralling R&D costs, according to industry guru Bernard Munos.
Lonza has launched a service to help biopharmas decide if promising protein drug candidates are worth developing, from an immunogenicity and manufacturing standpoint.
DKSH has upgraded its cold chain infrastructure in Southeast Asia as both small and large manufacturers increase their access needs to emerging markets.
Globalisation, outsourcing and a move towards biopharmaceuticals are leading innovation for pharma distribution companies, according to DHL Global Forwarding.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Lonza and SynteractHCR.
Fujifilm Diosynth Biotechnologies has partnered with Piramal Healthcare on development and manufacture of ADCs.
SGS Life sciences has doubled testing capacity at its New Jersey, US laboratory citing pharma demand for both routine and complex analysis services.
Marken is looking at setting up a home delivery service as a further expansion of its clinical trial and logistics offering.
News from Patheon, CTI and PRECOS – People on the move
Outsourcing Pharma presents its weekly round-up of the latest new faces and appointments in the pharmaceutical industry, including news from Patheon, CTI and PRECOS.
News from Patheon, Wolfe Laboratories, and Premier Research – People on the move
Outsourcing-Pharma presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Patheon, Wolfe Laboratories, and Premier Research.
PhRMA backs FDA plans for biosimilar fees discussion
US drug industry group PhRMA has backed FDA plans to discuss fees for biosimilars with pharmaceutical manufacturers.
Quintiles says the Russian pharmaceutical market is at a tipping point and poised for significant expansion over the next decade.
Unilife says device selected for new biologic trial
Unilife says its one of its technologies has been selected as the delivery device for a biologic drug in an upcoming clinical trial.
DavosPharma teams with Immunologix on 100% human MAbs for discovery
Chemistry services provider DavosPharma has added 100 per cent human antibodies to its discovery offering through a new alliance with Immunologix.
A new role for former Genzyme CEO and a leadership change at Astellas Europe – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a new role for former Genzyme CEO and a leadership change at Astellas Europe.
UK CROs extend preclinical cancer partnership
Preclinical Oncology Services Limited (Precos) will to work with discovery services firm Argenta Discovery on cancer drug development projects under a revised collaboration agreement announced late yesterday.
Appointments at Catalent, Cytel and Laureate Biopharmaceutical – People on the move
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Catalent, Cytel and Laureate Biopharmaceutical.
CRL expands cancer model offering with p53 and BCrp rats
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
Cancer Research UK opens biopharm production unit
Cancer Research UK has established a £18m ($28.4m) biopharm manufacturing unit to produce complex experimental drugs, such as monoclonal antibodies.
Regulus’ microRNA wins potential $750m Sanofi deal
Regulus Therapeutics’ microRNA satellite technology has won the firm its biggest deal to date with French drugmaker Sanofi-Aventis agreeing a development accord worth up to $750m (€606m).
Florida Biologix wins ASC-101 contract
US CMO Florida Biologix (FB) says its new contract with America Stem Cell (ASC) shows that demand for trial-phase biologics manufacturing is starting to recover.
Wacker expands cyclodextrin capacity
Wacker has brought its expanded cyclodextrin facility online following its $21m (€15m) expansion, which has significantly increased capacity in response to growing demand for the excipient.
AstraZeneca becomes Jubilant’s latest JV partner
AstraZeneca (AZ) has become the latest company to enter into a research collaboration with Jubilant, with the companies initially focusing on delivering preclinical candidates in the neuroscience area.
Bosch makes liquid filling a disposable option
The use of disposable manufacturing equipment in pharmaceutical
production and greater need for containment equipment were
recurring themes at the Interphex show in Philadelphia last week,
and both were addressed by new equipment...
Ignoring downstream processing hikes costs
The contract manufacturing market for biologicals will more than
double over the next six years, but production costs are higher
than necessary because 'downstream' processing is being ignored.
KS Avicenna offers biomanufacturing services
KS Avicenna, the Canadian unit of KS Biomedix of the UK, launched a
newly expanded contract biopharmaceutical manufacturing facility in
Canada, to service both North American and European clients, at the
start of the BIO 2003 meeting,...
Biotechs - facing up to reality
The bulk of biotech companies are firmly rooted towards the foot of
the ladder of corporate evolution. Precious few can realistically
claim to be at the top end of the evolutionary scale with full
R&D capabilities, global reach...